CD43
- Known as:
- CD43
- Catalog number:
- 1F-220-T025
- Product Quantity:
- 25 tests
- Category:
- -
- Supplier:
- Exbio
- Gene target:
- CD43
Related genes to: CD43
- Gene:
- SPN NIH gene
- Name:
- sialophorin
- Previous symbol:
- -
- Synonyms:
- LSN, CD43, GPL115
- Chromosome:
- 16p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1988-08-31
- Date modifiied:
- 2016-07-19
Related products to: CD43
Related articles to: CD43
- More than 200 monoclonal antibodies (mAbs) are approved for clinical use, yet their therapeutic potential is constrained by dependence on repeated injections or infusions that drive nonadherence, limit access in low-resource settings, and generate peak-trough pharmacokinetics linked to adverse effects and reduced efficacy. Here, we developed an immunomodulatory, encapsulated cell-based "biologics factory" that overcomes mAb instability, immunogenicity, and the fibrotic foreign body response that have limited previous approaches, enabling continuous in situ production of therapeutic antibodies from a single administration. Screening chemically modified alginate biomaterials in immunocompetent mice identified a lead immunomodulatory alginate formulation that sustains stable serum titers of the HIV-neutralizing mAb 3BNC117 for 1 year. Single-cell RNA sequencing revealed that this formulation promotes a local anti-inflammatory, proresolving immune niche that attenuates fibrosis. The platform's versatility was demonstrated by the production of 13 diverse mAbs from an allogeneic cell chassis, with sustained in vivo delivery of a subset including ipilimumab, pembrolizumab, adalimumab, and PGT121. Integration into a retrievable macrodevice enabled on-demand therapeutic termination and reimplantation for dose-proportional tuning. In a nonhuman primate, subcutaneous implantation maintained stable ipilimumab titers for more than 6 months with no detectable toxicity, antidrug antibodies, or adverse events, and dose-dependent exposure was confirmed across a three-dose escalation. These results demonstrate a clinically translatable platform that offers a practical strategy to replace frequent injections with single-administration therapy. A cell-based delivery platform within an antifibrotic minimally invasive device enables year-long mAb delivery. - Source: PubMed
Publication date: 2026/10/02
Fell CodyDavis Anthony EPandey ShaliniGuinn Michael TWang ZeshiDeBonis JonathonSmith ChancellorBrown NathanMurungi DannaKim YeonjuMohandessi ImaanBednarz PatrickArdeshir AmirHaupt Erin MCuevas Samuel ILavine Christy LSeaman Michael SIgoshin OlegGhanta Ravi KDiehl Michael RVeiseh Omid - Solid pseudopapillary neoplasm (SPN) of the pancreas occurs predominantly in young women and commonly contains hemorrhagic and degenerative components that can complicate imaging assessment. We report the case of a 19-year-old woman who presented with abdominal distension and decreased appetite. Multiphasic abdominal CT, including an unenhanced phase, demonstrated a well-circumscribed cystic and solid mass in the pancreatic head, with internally hyperattenuating areas on the unenhanced images and mild heterogeneous enhancement of the non-cystic component. MRI demonstrated peripheral and internal intrinsic T1 hyperintensity, compatible with blood products, markedly heterogeneous T2 signal, and restricted diffusion in a non-cystic portion that also showed post-contrast enhancement, along with an enhancing capsule. The measured apparent diffusion coefficient (ADC) was approximately 0.98 × 10⁻³ mm²/s. Because clotted blood may also restrict diffusion, the diffusion-weighted imaging (DWI) and ADC findings were interpreted together with the conventional and post-contrast images rather than being used alone to identify viable tumor tissue. The patient underwent laparoscopic pancreaticoduodenectomy. Gross examination revealed a cystic and solid tumor containing abundant bloody fluid, and microscopy confirmed conspicuous hemorrhage. Immunohistochemistry showed nuclear and cytoplasmic β-catenin positivity, nuclear progesterone receptor positivity, and CD10 and vimentin positivity, supporting the diagnosis of SPN. Resection margins and sampled lymph nodes were negative. Correlative analysis of CT and MRI findings with pathological and immunophenotypic features may improve diagnostic confidence. - Source: PubMed
Publication date: 2026/08/31
Ma HaoYin JiaxinZhang Xianglin - Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare pancreatic tumor with low-grade malignant potential. It predominantly occurs in adolescent girls and young women but can also affect boys. SPN may contain hemorrhagic or cystic components that can be mistaken for a post-traumatic hematoma when patients present after abdominal injury. We report a 12-year-old boy whose pancreatic tail lesion was initially interpreted as a traumatic retroperitoneal hematoma after minor blunt trauma at age 7. Ultrasound-guided drainage yielded hemorrhagic fluid with non-elevated amylase levels and negative bacterial culture; however, cytological examination was not documented. The lesion persisted, and scheduled follow-up was subsequently discontinued. Approximately 4.5 years later, repeat evaluation demonstrated interval enlargement from approximately 5.6 cm to 10 cm. Imaging showed a complete thin capsule, mixed solid-cystic architecture, coarse calcification, and progressive enhancement, features that were not compatible with a resolving hematoma. After multidisciplinary reassessment, SPN was considered the most likely diagnosis. Laparoscopic spleen-preserving distal pancreatectomy was successfully performed, with an estimated blood loss of 30 mL. Histopathological examination confirmed SPN, with a Ki-67 index of approximately 2%, a negative stapled margin, and no tumor involvement in the sampled adjacent pancreatic or fibrofatty tissue. The patient did not develop a clinically relevant postoperative pancreatic fistula. During approximately 11 months of postoperative surveillance, no recurrence was detected. This case emphasizes that a presumed post-traumatic hematoma should be reassessed when it persists or enlarges. It also supports the feasibility of minimally invasive spleen-preserving resection in carefully selected pediatric patients. - Source: PubMed
Publication date: 2026/09/16
Zhou ZhaoweiPan RifangLi JunzhongLi ZhaopanXiao Zhihua - Biocatalytic regioselective acylation is a powerful strategy for diversifying natural products and optimizing their pharmacological properties. Compared with plant acyltransferases (ATs), bacterial tailoring ATs remain poorly understood. AntB from the antimycin pathway was previously reported to possess acyl-donor promiscuity toward limited acyl-CoA thioesters, yet its acyl-acceptor promiscuity, structural basis, and catalytic mechanism had not been elucidated. Here, we systematically characterize AntB and uncover its remarkable dual substrate promiscuity. The enzyme accepts eight structurally diverse natural product acceptors-including terpenoids, alkaloids, polyketides, and aromatics-and supports iterative acylation, while also processing 43 chemically distinct acyl donors, including 22 previously unreported. Structural analysis revealed the molecular basis of its dual substrate promiscuity and catalysis. Engineering afforded the S17A/M265L variant with a 4.45-fold increase in activity toward SPN-J acylation. To harness this catalytic flexibility, we developed a one-pot biocatalytic platform by combining AntB with engineered acyl-CoA synthetases UkaQ and AliA for in situ acyl-CoA regeneration. Application of this system to the late-stage modification of the agrochemical precursor deacyl-UK-2A generated a panel of acylated analogues, including three novel derivatives with enhanced antifungal activity. This study advances understanding of bacterial tailoring ATs and establishes AntB as a versatile biocatalyst for late-stage natural product diversification. - Source: PubMed
Publication date: 2026/09/30
Zheng MengmengDai YuhanLi XiangyuDu YeqingZhu HuchengLi LeiWei GuangzhengQu Xudong - Fucoxanthin (FX), a hydrophobic marine carotenoid, exhibits low stability and oral bioavailability under harsh conditions. A pH-responsive sodium alginate-xanthan gum (SA/XG) hydrogel incorporating soy protein nanoparticles (SPN) was fabricated for FX stabilization and intestinal-targeted release. SA/XG ratio and intermolecular interactions govern its physicochemical performance. The optimal hydrogel was formulated with SPN obtained after 1.5 h of enzymatic hydrolysis, 1.5% (w/v) sodium alginate, and 1.5% (w/v) xanthan gum at an SA/XG volume ratio of 2:1. It exhibited an encapsulation efficiency of 78.47 ± 2.11%. In vitro digestion resulted in minimal FX release in simulated gastric fluid, whereas 83.85 ± 1.01% of FX was released in simulated intestinal fluid. The Korsmeyer-Peppas model indicated that the release was primarily governed by hydrogel swelling and Fickian diffusion. SPN/FX/SA/XG hydrogel extract showed >90% HaCaT cell viability (negligible cytotoxicity), enabling efficient FX encapsulation and sustained release for oral-food use. - Source: PubMed
Publication date: 2026/09/26
Lu YujingWang BaijieRen JiayingPiao HuiyingMa SaijieMa XiaoyanBai ShuangQi Hang